tara

tara
LA Mayor's Office Acknowledges the NDF's Advocacy with GNEM

Thursday, July 31, 2014

Abdullah's Impressive Journey of Living with HIBM

Dear friends, this is my friend Abdullah's story of his life with HIBM.  As I get to meet and know other friends with this rare disease, I have become increasingly touched, and  humbled to hear their stories.  I have learned more about my suffering by listening, relating, and sharing our similar challenges. Thank you Abdullah for sharing with us.





Abdullah's Story:


     This might be the first time that I am telling my detailed story and battle with HIBM disease. Actually, I have known about this disease since I was a child.  Maybe not under its current name, but I definitely knew already what it could do and how it could hurt.
     I was exposed to its different phases through forty years of my life.  My first introduction was when I was five. At that age I saw my father arriving at our village after a long time of disappearance for medical treatment in the city as I was told.
     I saw my father then pulling up his legs from the ground, trying to walk, and struggling to prevent himself from falling on the narrow rocky walkways of our village with two of our relatives standing on each sides near him ready to help. I knew by then that my father was different, such that his return turned out to be a sad occasion.
     I got used to my father being physically weak, so I got used to being careful when I played with him or got close to him since just a little bump could make him fall down. This disease somehow became part of my life ever since.
     Time flew and months turned into years. I grew up quickly and completed my college training to become a naval officer. I was even lucky enough as to make my dream come true:  joining the Naval Flight School to become a pilot for the Navy.
     During my flight school days and when I was 22, I started to notice some strange signs of becoming easily fatigued after running or heavy exercises. I was really athletic at that time, and I thought of many reasons for these strange body responses, but I never came close to the thinking that I had a muscle disorder similar to what my father had.
     I had earned my wings and have flown (Navy) aircraft for three years.   However, the symptoms of weakness and improper functioning of my lower limbs continued to grow, but I kept denying those realities, and resisted visiting a doctor, possibly because I suspected the answer all along.
     It did not last long before I had to see a flight physician for an annual flying medical checkup. Once the doctor completed his routine checkup and started to sign my “fit to fly sheet”, he asked “did you suffer from any problems?"  I answered him with painful feelings, "I believe that I am not safe to fly."  “Why,” the surprised doctor asked.  I mentioned to him that I didn't really know what was the matter, but my legs muscles were not strong enough to prevent my feet from dropping. The doctor then sent me to a neurologist to diagnose my case.
     In my visit to the neurologist, I remember that he came out to welcome me and, as I was walking to his exam room he was observing my walking style.   He surprised me with this question: “Do any of your parents have a muscular problem?" Before my “yes” answer and in those very few seconds of pause I realized that my flying days were over and my whole life would not be I had hoped.
     With no doubt, the diagnosis was thus muscular dystrophy, which later was correctly confirmed as HIBM. The disease that had weakened my father’s body had just begun to do its destruction on my young body.
 
     The fact that I was almost fit and having only minor walking problems, and simultaneously recognizing that I would soon be in a wheelchair was not an easy idea for me to accept.   Adapting to the whole idea of living perpetually with a disability was indeed a very difficult journey.
     It took me a couple of years to accept HIBM as part of me, and it took me a few years more trying to ignore it and continue my life.  Naturally, at first it was very hard to deal with this illness.  Often I just I hated the ever progressing mobility limitations that  that restricted what I could do, and  it changed my life style.  However, my God (Allah) gave me the required acceptance and the satisfaction to realize that this was my fate, and that  I should appreciate the other gifts that were given to me.
     With extraordinary support from my wife without whom I could not imagine my life plus the support of my great family and friends, I was able to positively turn my life around and focus on my achievements. With a successful marriage, five wonderful kids, and recognized educational and career successes, there was no reason for me to complain.
      Although I am trying to enjoy each day of my life as it comes along,     my hope is to get stronger.  I fervently hope in the near future a               treatment will be available for myself and others who suffer from             HIBM.
 

    Sunday, July 27, 2014

    Gne Myopathy Study in France And a Patient's Summit in September

    Dear Friends:
         Here is an HIBM study that is taking place in France.  Please check the hyper-link for specific information.

    Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE) (ClinBio-GNE)
    Contact: Teresa Gidaro, MD PhD+33 1 42 16 66 48t.gidaro@institut-myologie.org




    Location:  France
    Institute of MyologyRecruiting
    Paris, France, 75013
    Principal Investigator: Teresa Gidaro, MD PhD        
    https://clinicaltrials.gov/ct2/show/NCT02196909?term=hibm&rank=5


         There will be a rare patient's advocacy summit to be held in Huntington Beach, California on  September 11-12, 2014.  For those who are unable to attend, there will be live streaming on the days  of the summit.  I have attached the link below.

    2014 RARE Patient Advocacy Summit

    RARE Patient Advocacy Summit
    divider
    Please join us for our
    3rd Annual “RARE Patient Advocacy Summit
    held on September 11-12, 2014
    at the Hyatt Regency in Huntington Beach, California.
    Empowering Patient Advocates to Become Successful Activists
    http://globalgenes.org/2014-rare-patient-advocacy-summit/

    Saturday, May 3, 2014

    Slide and Poster Presentation at the American Academy of Neurology Meeting by Ultragenyx

    Ultragenyx, the bio-pharmaceutical company conducting the clinical trial with Sialic Acid -extended release and immediate release has announced positive data from their phase 2 study,  The company presented some of this information prior to this, however the data now seems to have more details.




    I hope the graphs and charts I have posted here are legible. Please feel  free to contact me if you have any questions.                                                



    Thursday, February 27, 2014

    National Institutes of Health to Host a Series of Events to Address Rare Disease Day



    The NIH will be celebrating Rare Disease Day on February 28th.  There are over 6500 rare diseases.  The event is free to the public and is held at the NIH in Bethesda, Maryland.  I have attached the link.
    https://events-support.com/Documents/AGENDA_RDD14.pdf



    Wednesday, February 26, 2014

    A Conglomeration of List of Links and Updates On HIBM (GNE Myopathy)

    It appears that rare diseases are getting more coverage in the media and bio-pharmaceutical companies are willing to take on the tasks of research and drug trials
    .http://www.phrma.org/working-together-we-can-produce-results

    1.  Ultragenyx, the company that is conducting the Sialic Acid (extended and immediate release) tablets for HIBM has started trading their stock on Wall Street now.  They use the ticker symbol RARE.  Here is a link on their presentation and an upcoming event.  On March 5th they will be having a  Health care conference of which it seems one could register for.
      http://ir.ultragenyx.com/events.cfm

    2.  The LA Marathon will be happening on March 9th. and there is a site set up for those who would like to participate or donate. http://www.crowdrise.com/runforhibm2014/fundraiser/sandradarvish

    3. Ultragenyx is recruiting participants for a Combined Registry Prospective Natural History Study.  They are recruiting participants in the United Kingdom, Canada, and the United States.  I see also listed are France and Bulgaria  however they are not recruiting yet.  Here is the link:
    http://clinicaltrials.gov/ct2/show/NCT01784679?term=hibm&rank=2

    4.  The National Institutes of Health still seems to be recruiting for their natural history study:
    http://clinicaltrials.gov/ct2/show/NCT01417533?term=hibm&rank=4

    5.  There is support group on  facebook for patients and family with HIBM.  This is a very helpful group of people who offer tips on how to manage our disease.  We also started a Google hangout group and this was quite informative to see and chat with others.

    Please feel free to contact me if you need more information in this blog.
    Thank you for visiting this blog.

    Monday, January 6, 2014

    Affordable Testing for HIBM Will Take Place in Los Angeles, California on January 12th. 2014


    For those who  are living in Los Angeles, California  or can make there this weekend,  please use this opportunity to get tested for HIBM.
    NDF is proud to partner with Sinai Temple and the Los Angeles Jewish Genetic Disease Project to finally bring affordable genetic disease screening to Los Angeles. Together we can stop HIBM from passing to the next generation.
    Please refer to this link.

    https://www.facebook.com/events/397791307033701/

    Saturday, December 28, 2013

    End of 2013 With Promising Developments in Research and Trials of HIBM/GNE Myopathy

    Dear friends, family and readers:
    I wish you a joyful conclusion to 2013 and  may 2014 bring you joy, good tidings, and peace. I continue to forge ahead  with my participation in a clinical trial for HIBM.
    There has been some progress with the clinical trials conducted by NIH and Ultragenyx Pharmaceutical.  NIH concluded the phase 1 trial with ManNac and will be starting phase 2 in the near future.  Ultragenyx Pharmaceutical has concluded extended phase 2 with the Sialic Acid Extended Release SA-ER tablets and has started patients on Sialic Acid Immediate Release (SA-IR) in addition to the SA-ER tablets.  The total dose per day is 12,000 mg. In addition to the 46 patients who were in the trial already, they are recruiting 10 new patients -"treatment naïve subjects" (those who have never taken sialic acid)  for this current trial.  Here is the link with the details.

    http://clinicaltrials.gov/ct2/show/NCT01830972?term=hibm&rank=5


    Ultragenyx Pharmaceutical  found the following based on preliminary data in phase 2 trial which is quite promising.
    "Similar to the results observed at the 24-week interim analysis, at 48 weeks the
    comparison of the upper extremity composite of muscle strength for the combined
    group of patients on 6 grams showed a modest increase and a statistically significant
    difference relative to the decline in strength observed in the combined groups on 3
    grams. In the 6-gram cohort treated for 48 weeks, the modest increase in upper 
    extremity strength observed at 24 weeks was sustained relative to a further decline in 
    the comparable 3-gram group. These changes were more pronounced in those patients
    that have less advanced disease as assessed by a greater walking ability at baseline, a
    predefined subset. The lower extremity composite did not show a statistically significant
    difference between the dose groups, but neither group showed a significant decline
    during the treatment period."

    These 48 week data suggest that 6 grams per day of SA-ER is mitigating the normally 
    expected decline in upper extremity muscle strength,” said Emil Kakkis, M.D., Ph.D.,
    Chief Executive Officer of Ultragenyx. “The maintenance of this effect from the 24-week
    data is encouraging. Given the difference between the dose groups and good safety
    profile, we plan to test an even higher dose of sialic acid in these patients who have no
    other approved treatment options.”
    I have attached the link of their complete press release here.
    http://www.ultragenyx.com/index.php?ht=a/GetDocumentAction/i/17531


    The acronym HIBM (Hereditary Inclusion Body Myopathy) has been widely used to describe the muscle wasting disease and  also has been confused with another disease, therefore the name of HIBM is now changed to GNE myopathy which more accurately defines this disease as it is on this gene - GNE where the deficiency happens. I will gradually change my blog name to "Tara Talks GNE Myopathy". Here is some discussion on this topic.

    "There is confusion in some circumstances with the very similar names of two quite different medical disorders; Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. This press release is to advise that Inclusion Body Myositis is NOT THE SAME as HIBM (myopathy). Because of this confusion, NZP supports the name change of Hereditary Inclusion Body Myopathy (HIBM) to “GNE myopathy” (see; http://dx.doi.org/10.1016/j.ymgme.2012.10.011).
    Myositis is a mostly inflammatory muscle disease and mostly occurring sporadically in elderly people. There is no inflammation in HIBM/GNE myopathy and GNE myopathy has a much earlier onset than myositis. Also HIBM/GNE myopathy is a genetic disease, while for Inclusion Body Myositis no common genetic component has been identified.
     
    To make the names more confusing, inclusion body myositis is abbreviated as sIBM (sporadic inclusion body myositis). More about sIBM can be found at: http://omim.org/entry/147421.
    In some publications, Inclusion Body Myositis is called IBM1 and HIBM/GNE myopathy is called IBM2."

    http://www.nzp.co.nz/index.php/news/7-news/79-ibm-hibm-and-gne-myopathy.html

    "GNE myopathy, previously termed hereditary inclusion body myopathy (HIBM), is an adult-onset neuromuscular disorder characterized by progressive muscle weakness. The disorder results from biallelic mutations in GNE, encoding UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, the key enzyme of sialic acid synthesis. GNE myopathy, associated with impaired glycan sialylation, has no approved therapy. "

    http://www.sciencedirect.com/science/article/pii/S1096719212003794


    Best wishes for 2014.





    Saturday, November 16, 2013

    A Profoundly Touching Video of a Friend with HIBM

    This is quite a moving video of a friend who also has HIBM.  She gave this speech at the annual fundraising gala event for the Neuromuscular Disease Foundation.  http://www.ndf-hibm.org/

    The video is about thirteen minutes long.  In her speech Jennifer poignantly describes what it is like to inhabit  a body that suffers from HIBM. She has effectively encapsulate  the whole spectrum of feelings of HIBM patients and their daily challenges.

    Please take the time to watch this video, and visit the NDF web site.
    Thank you Jennifer. 
    http://vimeo.com/79357093

    Sunday, November 3, 2013

    A More Functional Sleek Designed Wheel Chair With Reviews From Gizmodo


    Finally, a wheel chair is coming on the market with functionality and "good looks" for people with disabilities.  I feel this company has done it's research in how people could more effectively use a wheel chair that assists in maintaining proper posture, ease in getting up, and sitting down. I had the pleasure of meeting one of it's founder and I am impressed with their vision to create this chair. Check out the wheel technology and the turning radius.  I do not know the cost for such a chair yet and if and when Medicare will cover it.  Please feel free to contact the company.
    Best wishes to all my readers.  May your light continue to shine.
    Tara

    http://whill.jp/


    Type-A is classified as a non-medical device. So, people will need to buy WHILL Type-A out of pocket... We plan to receive FDA clearance with our future model and already got started with it.


    Review of this chair by Gizmodo
    http://gizmodo.com/this-professor-x-approved-futuristic-wheelchair-is-arri-1450704347

    Friday, October 11, 2013

    Friend from Japan with HIBM/gne Myopathy, Japanese Registry, and Recent Research on HIBM

     I recently had the pleasure of meeting a friend from Japan who like me has HIBM. Yuriko travelled to the United States to visit  the National Institutes of Health in Bethedsa, Maryland and attend a HIBM symposium held in San Francisco, California. Yuriko started noticing weakness associated with HIBM in her early twenties and is the only one in her family affected.  She currently uses  a wheel chair and is getting weaker as this disease progresses.  She is the vice president for  the Patients Association for Distal Myopathies or PADM in Japan. This is a patient organization which is very active in pursuing a treatment for HIBM.  There are over 130 members in this  association which is quite a high number for a rare disease. There are two well known researchers of HIBM  (Dr. I. Nishino and Dr. I. Nonaka)  on their Academic Advisory board.

    It was very insightful to meet Yuriko and her husband.  I find Yuriko  brave to travel such a long distance, as in my experience  with my disability a flight of only five hours is my limit.  There are many barriers at the airports, getting on and off  the plane for one to overcome when using a wheelchair.  It was  quite insightful for me to meet another patient with HIBM and observe how gracefully Yuriko is able to manage her disability.





    Link for the PADM association.
    http://enigata.com/index_e.html

    There is a Japanese GNE myopathy registry which was set up in 2012. 
     http://www.remudy.jp/dmrv/index.html

    A research abstract recently published on Japanese patients.
    I find this  information quite interesting from this abstract that there were able to profile 212 patients as with rare diseases it is quite difficult to get that many patients.. "Here, we report the mutation profile of the GNE gene in 212 Japanese GNE myopathy patients, which is the largest single-ethnic cohort for this ultra-orphan disease. We confirmed the clinical difference between mutation groups. However, we should note that the statistical summary cannot predict clinical course of every patient."
    http://europepmc.org/abstract/MED/24027297

    Just a personal note to my friends from far and near,  I continue to participate in a clinical trial in the U.S and I am well.